# EDGAR Filing Document

**Accession Number:** 0001611747
**File Stem:** 0001178913-26-001165
**Filing Date:** 2026-3
**Character Count:** 10660
**Document Hash:** 591e025ec5c483f4006c85c147962b09
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001178913-26-001165.hdr.sgml**: 20260415

**ACCESSION NUMBER**: 0001178913-26-001165

**CONFORMED SUBMISSION TYPE**: 3

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20260318

**FILED AS OF DATE**: 20260318

**DATE AS OF CHANGE**: 20260318

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Green Jay
- **CENTRAL INDEX KEY:** 0001960710

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 3
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-37353
- **FILM NUMBER:** 26766413

**MAIL ADDRESS:**
- **STREET 1:** 354 CONCESSION 10 E
- **CITY:** FREELTON, ON
- **STATE:** Z4
- **ZIP:** L8B 1H6
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Scinai Immunotherapeutics Ltd.
- **CENTRAL INDEX KEY:** 0001611747
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** L3
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** JERUSALEM BIOPARK, 2ND FLOOR
- **STREET 2:** HADASSAH EIN KEREM CAMPUS
- **CITY:** JERUSALEM
- **STATE:** L3
- **ZIP:** 00000
- **BUSINESS PHONE:** 972-8-9302529

**MAIL ADDRESS:**
- **STREET 1:** JERUSALEM BIOPARK, 2ND FLOOR
- **STREET 2:** HADASSAH EIN KEREM CAMPUS
- **CITY:** JERUSALEM
- **STATE:** L3
- **ZIP:** 00000

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** BiondVax Pharmaceuticals Ltd.
- **DATE OF NAME CHANGE:** 20140624

## Ex-24

------

<u>**Exhibit 24**</u>

**** 

<br> **LIMITED POWER OF ATTORNEY**

<br> Know all by these present, that the undersigned hereby constitutes and appoints each of Amir Reichman and Uri Ben-Or (each, an "***Attorney-in-fact***"), or any of them acting singly and with full power of substitution, as the undersigned's true and lawful attorney-in-fact to:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. prepare, submit, execute for, and on behalf of the undersigned, in the undersigned's capacity as an officer or director, as applicable, of Scinai Immunotherapeutics Ltd. (the "Company"), (a) Forms 3, 4, and 5 (and any amendments thereto) in accordance with Section 16(a) of the Securities Exchange Act of 1934, as amended, and the rules promulgated thereunder and (b) any other forms or reports the undersigned may be required to file in connection with the undersigned's ownership, acquisition, or disposition of securities of the Company with the Securities and Exchange Commission (the "SEC") on the Electronic Data Gathering, Analysis, and Retrieval system ("EDGAR") of the SEC;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4, or 5, or other form or report (or any amendment thereto), and timely file such schedule, form or report with the SEC on EDGAR and any stock exchange or similar authority;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. seek or obtain, as the undersigned's representative and on the undersigned's behalf, information on transactions in the Company's securities from any broker or financial institution, and the undersigned hereby authorizes any such person to release any such information to each of the Attorneys- in-fact and approves and ratifies any such release of information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4. take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such Attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such Attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such Attorney-in-fact may approve in such Attorney-in-fact's discretion.

The undersigned acknowledges that this Power of Attorney authorizes, but does not require, the Attorney-in-Fact to act in his or her discretion on information provided to such Attorney-in-Fact without independent verification of such information, and any documents prepared or executed by the Attorney-in-Fact on behalf of the undersigned pursuant to this Power of Attorney will be in such form and will contain such information as the Attorney-in-Fact, in his or her discretion, deems necessary or desirable.

The undersigned hereby grants to each such Attorney-in-Fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such Attorneys-in-Fact, or such Attorney-in-Fact's designated substitute or substitutes, shall lawfully do or cause to be done by virtue of this Power of Attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing Attorneys-in-Fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is Scinai Immunotherapeutics Ltd. assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934, and this Power of Attorney does not relieve the undersigned from responsibility for compliance with the undersigned's obligations under Section 13 or Section 16 of the Exchange Act, including, without limitation, the reporting requirements under Section 13 or Section 16 of the Exchange Act.

This Power of Attorney, with respect to each of the Attorneys-in-Fact, shall remain in full force and effect until the earlier of (a) the date that the undersigned is no longer required to file Forms 3, 4, and 5 with respect to the undersigned's beneficial ownership and transactions in securities issued by the Company, (b) this Power of Attorney is revoked by the undersigned in a signed writing delivered to such Attorneys-in-Fact, or (c) the time at which such Attorney-in-Facts are no longer employed by Scinai Immunotherapeutics Ltd

------

IN WITNESS WHEREOF, the undersigned has executed this Limited Power of Attorney as of this 18<sup>th</sup> day of March, 2026.

SIGNED AND ACKNOWLEDGED

By: <u>/s/ Jay Green</u>

Name: Jay Green

------

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 3

### INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Green Jay<br><sub>(Last) (First) (Middle)</sub><br>C/O SCINAI IMMUNOTHERAPEUTICS LTD.<br>JERUSALEM BIOPARK, 2ND FLOOR<br><sub>(Street)</sub><br>JERUSALEM,  9112002<br><sub>(City) (State) (Zip)</sub> | **3. Issuer Name and Ticker or Trading Symbol**<br>Scinai Immunotherapeutics Ltd. [ SCNI ] | **5. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  |
| **2. Date of Event Requiring Statement (Month/Day/Year)**<br>2026-03-18 | **4. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[X] Director   [ ] 10% Owner<br>[ ] Officer (give title below)   [ ] Other (specify below)<br>_ _ | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities Beneficially Owned

---

|  |  |  |  |
| --- | --- | --- | --- |
| 1. Title of Security | 2. Amount of Securities Beneficially Owned | 3. Ownership Form | 4. Nature of Indirect Beneficial Ownership |

---

## Table II - Derivative Securities Beneficially Owned

---

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Underlying Securities | 3. Title and Amount of Underlying Securities | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| American Depositary Shares | <sup>(1)</sup> | <sup>(1)</sup> | Ordinary shares, no par value per share ("Ordinary Shares")<sup>(2)</sup> | 200000 | <sup>(1)</sup> | D |  |
| Stock Option (right to buy) | <sup>(3)</sup> | 2033-08-24 | Ordinary Shares | 1000000 | $0.005 | D |  |
| Stock Option (right to buy) | <sup>(4)</sup> | 2033-08-24 | Ordinary Shares | 8000000 | $0.005 | D |  |
| Stock Option (right to buy) | <sup>(5)</sup> | 2035-12-22 | Ordinary Shares | 48200000 | $0.0004 | D |  |

---

### Footnotes:

(1) Represents 50 American Depositary Shares, which are convertible at any time into 200,000 Ordinary Shares, at the holder's election and have no expiration

(2) The Ordinary Shares are represented by American Depositary Shares, each of which currently represents four thousand Ordinary Shares.

(3) The option vests in one installment on August 24, 2027, subject to the Reporting Person's continued service through such date.

(4) The option vests in three equal annual installments commencing August 24, 2025, subject to the Reporting Person's continued service through such dates.

(5) The option vests in three equal annual installments commencing December 22, 2026, subject to the Reporting Person's continued service through such dates.

**Remarks:**
Exhibit 24 - Power of Attorney.

**Signature:** /s/ Amir Reichman, Attorney-in-Fact  
**Date:** 2026-03-18

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**